Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corp ADR (NQ: LEGN )

63.16 -0.38 (-0.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 397,803
Open 64.01
Bid (Size) 61.25 (1)
Ask (Size) 65.24 (1)
Prev. Close 63.54
Today's Range 62.41 - 64.57
52wk Range 37.30 - 77.32
Shares Outstanding 308,456,852
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Latest Analyst Ratings for Legend Biotech
Via Benzinga
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire

Performance

YTD
+29.69%
+29.69%
1 Month
-8.54%
-8.54%
3 Month
-14.97%
-14.97%
6 Month
+37.13%
+37.13%
1 Year
+58.81%
+58.81%

More News

Read More
3 Biotech Stocks That Analysts Are Drooling Over
Via InvestorPlace
Legend Biotech to Host Investor Conference Call on Second-Quarter Results
From Legend Biotech Corporation
Via Business Wire
The Latest Analyst Ratings for Legend Biotech
Via Benzinga
The Latest Analyst Ratings for Legend Biotech
Via Benzinga
Legend Biotech's Breakthrough in Multiple Myeloma Study Prompts Positive Analyst Forecast
Via Benzinga
Expert Ratings for Legend Biotech
Via Benzinga
Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death
Via Investor's Business Daily
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO
Via Talk Markets
Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
Analyst's Verdict on Legend Biotech: Doubts On Commercial Execution, Long- Term Market Share
Via Benzinga
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
From Legend Biotech
Via Business Wire
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
Via FinancialNewsMedia
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2023
Via Benzinga
Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
From Legend Biotech Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
Via Benzinga
Legend Biotech Reports First Quarter 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conference
From Legend Biotech Corporation
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares
From Legend Biotech Corporation
Via Business Wire
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine
Via Benzinga
After Jumping 49% in 1 Month, Is It Too Late to Buy Legend Biotech?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.